Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — 43rd Annual J.P. Morgan Healthcare Conference (January 2025)
27 slides from Sutro Biopharma's conference presentation, January 2025
Slide 1: Sutro Biopharma at 43rd Annual J.P. Morgan Healthcare Conference
Sutro Biopharma 43rd Annual J.P. Morgan Healthcare Conference January 2025 Sutro Biopharma NASDAQ: STRO 1 NON CONFIDENTIAL
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than sta
Slide 3: Advancing Next-Generation ADCs with Proprietary Cell-free XpressCF Discovery Platform
3 Advancing Next-Generation ADCs with Proprietary Cell-free XpressCF® Discovery Platform Pipeline Luvelta: potential best-in-class tubulin inhibitor ADC for a range of FRα expressing cancers • Two registrational trials ongoing and multiple follow-on opportunities Proprietary Cell-free STRO-004 and N
Slide 4: Significant Near- and Long-term Opportunities for Broad Pipeline of Precisely Designed ADCs
Significant Near- and Long-term Opportunities for Broad Pipeline of Precisely Designed ADCs Luvelta Next-Generation ADCs: Pipeline-in-a-Product Potential Delivering Three INDs Over Next Three Years Lead Opportunity: Ovarian Cancer (Fast Track Designation) Three-pronged R&D strategy to enhance ADCs’
Slide 5: Well Capitalized with Strong Business Development Track Record Validating Cell-Free Platform
5 Well Capitalized with Strong Business Development Track Record Validating Cell-Free Platform in cash, cash equivalents & Funding generated from our (1) ~$388M marketable securities (2) ~$975M collaborators Over $2 Billion Potential Future Milestones plus Royalties Phase 2/3 vaccines for invasive P
Slide 6: Luveltamab Tazevibulin (Luvelta)
Luveltamab Tazevibulin (Luvelta) 6 NON CONFIDENTIAL
Slide 7: Luvelta: Precisely Designed Tubulin Inhibitor ADC with Potential to Address a Broader Patient Population
Luvelta: Precisely Designed Tubulin Inhibitor ADC with Potential to Address a Broader Patient Population of FRα-expressing Cancers Key Features Driving Luvelta’s Best-in-class Potential Receptor Hemiasterlin payload internalization • Tubulin inhibitor • High potency & ICD • High bystander killing •
Slide 8: Luvelta: Promising Clinical Activity in All FRα-Expressing Indications Evaluated
Luvelta: Promising Clinical Activity in All FRα-Expressing Indications Evaluated Estimated Annual Incidence in FRα-Expressing Patient Populations (U.S., Europe and Japan) Ovarian Cancer: ~69K NSCLC, Adenocarcinoma: ~108K Status: REFRαME-O1 Registrational Study Status: Phase 2 initial data expected 2
Slide 9: Luvelta: Opportunity to be First Therapy for ~80% of PROC Patient Population
Luvelta: Opportunity to be First Therapy for ~80% of PROC Patient Population with Lower TPS≥25% Threshold Luvelta Potentially Doubles the Addressable PROC Patients Patients with Platinum-Resistant Ovarian Cancer 80% • Luvelta has demonstrated clinical activity in PROC patients with FRα ≥25% of any s
Slide 10: Significant Opportunity for Luvelta to Become Best-in-Class, With Clear Commercial Path
Significant Opportunity for Luvelta to Become Best-in-Class, With Clear Commercial Path Approved FRα ADC Luvelta Addressable 35% of PROC patients 2 80% of PROC patients 1 Patient (TPS of ≥75% FRα, 2+ TPS ≥25% FRα at any Luvelta: Population staining intensity) staining intensity Tolerability Black bo
Slide 11: Registrational Strategy Supported by Clinical Data from ~100 Patients
Registrational Strategy Supported by Clinical Data from ~100 Patients Maximum Reduction in Tumor Target Lesions in RECIST-Evaluable Patients (N=92 Evaluable) 20% 3 in 5.2, 2 in 4.3, 2 in <=2.9, and 1 in >=5.6mg/kg -30% Partial response Ovarian Cancer Patients Total (N = 99) Platinum Sensitive 21 (21
Slide 12: REFRαME-O1 Enrollment Progressing Ahead of Internal Projections
REFRαME-O1 Enrollment Progressing Ahead of Internal Projections Active Countries Planned Countries* Trial Sites/Enrollment Austria Italy Australia Phase 3 randomized part 2 Belgium Poland enrollment tracking ahead of Canada internal projections Bulgaria Spain Isr ael Czech Republic Sweden Over 200 s
Slide 13: REFRαME-O1 Dose Optimization: Confirms Luvelta's Robust Response in PROC Patients
REFRαME-O1 Dose Optimization: Confirms Luvelta’s Robust Response in PROC Patients with FRα ≥25%, Selected Starting Dose of 5.2 mg/kg Topline Results from Efficacy Evaluable Patients (5.2 mg/kg group; N = 25)* Patient Profile Efficacy Profile Safety Profile • ~1/2 of the patients treated were • Achie
Slide 14: Luvelta Demonstrated Anti-Tumor Activity and Manageable Safety in Lower and Variable FRα Expressing Tumors
Luvelta Demonstrated Compelling Anti-Tumor Activity and Manageable Safety Profile In Lower and Variable FRα Expressing Tumors Bevacizumab Combo in Ovarian Cancer RAM AML1 NSCLC N = 17 N = 25 Preclinical Median PFS 8.3 months; 55.6% ORR at RP2D Meaningful clinical responses, including complete Single
Slide 15: STRO-004 & Next-Gen ADCs
STRO-004 & Next-Gen ADCs Leveraging Cell-Free Platform to Deliver Three INDs Over the Next Three Years 15 NON CONFIDENTIAL
Slide 16: Wider Therapeutic Index Achieved with Sutro's Cell-free ADC Platform
Wider Therapeutic Index Achieved with Sutro’s Cell-free ADC Platform Key Sutro Technologies to Improve ADCs Outside the Tumor Linker & payload design MTD ADC Click chemistry Site specific conjugation MTD ADC Antibody engineering TI TI MED ADC Focused R&D Strategy – Make ADCs Better Inside the Tumor
Slide 17: XpressCF Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms
XpressCF® Platform has Unique ADC Performance Capabilities Over Other Topo1 ADC Platforms Beta-Glu ADC2/ iADC/ Site HT DAR>8 Fc Silent Bispecific Linker Dual LPs iSAC Specific Screening Abbvie AstraZeneca Daiichi Sankyo Dualitybio Genequantum Genmab Gilead Hansoh Hengrui Kelun Lilly Medilink Merck K
Slide 18: STRO-004: Next Generation Tissue Factor-Targeting Exatecan/Topo1 ADC
STRO-004: Next Generation Tissue Factor-Targeting Exatecan/Topo1 ADC with Enhanced Therapeutic Potential Optimally Designed for Improved Clinical Benefits, Increased Tolerability Leads Enhanced Stability, Potency and Tumor Selectivity to Enhanced Drug Exposure • Exatecan payload: Clinically validate
Slide 19: Tissue Factor is Broadly Expressed Across Multiple Solid Tumor Indications
Tissue Factor is Broadly Expressed Across Multiple Solid Tumor Indications, Presenting Opportunity for Pan-Tumor Targeting Broad Opportunity for TF in Many Solid Tumors of Significant Unmet Need • TF expression has been associated with poor disease prognosis and increased metastatic properties • Cli
Slide 20: STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models
STRO-004 DAR8 Exatecan Achieved Sustained Tumor Regressions in Xenograft Models of NSCLC and HNSCC at Low Doses Lung (TF+++) Head and Neck (TF++) H1975 Growth Curves Detroit562 Growth Curves 1500 1500 (mm3)3) (mm33)) 1250 1250 Volume(mm volume(mm 1000 1000 Tumor Volume TumorVolume 750 750 500 500 Tu
Slide 21: STRO-004 Demonstrated Reduced Platform and On-target Toxicity
STRO-004 Demonstrated Reduced Platform and On-target Toxicity Due to Site Specific Conjugation and Beta Glu Linker-Payload Technology STRO-004 Tolerability Profile vs. Approved aTF ADC Eye Inflammation Skin Toxicities STRO-004 (DAR8-exatecan) Approved aTF ADC (DAR4-MMAE) 21 NON CONFIDENTIAL
Slide 22: Dual-Payload ADCs: Combining Payloads to Overcome Resistance
Dual-Payload ADCs: Combining Payloads to Overcome Resistance Potential Advantages of Dual-Payload ADC Approach Reduced Toxicity Reduced Clinical Complexity Simultaneous Payload Delivery Overcome Resistance Mechanisms 22 NON CONFIDENTIAL
Slide 23: Dual Payload ADC Displayed Enhanced In Vivo Efficacy in Ovarian Cancer
Dual Payload ADC (Topo1i + anti-Tubulin) Displayed Enhanced In Vivo Efficacy in Ovarian Cancer IGROV-1 - Tumor Growth IGROV-1 - Survival IGROV-1 - Time to Tumor Quadrupling Relative Tumor Volume (%) 1500 100 100 Percent Survival Percent survival 75 75 1000 50 50 500 25 25 0 0 0 0 20 40 60 80 100 0 2
Slide 24: iADC: Combines Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator
iADC: Combines Tumor-Targeted Delivery of a Cytotoxin and Immune Stimulator Strategic Partnership with Astellas to Deliver a New Treatment Option for Cold Tumors and Patients Unresponsive to Existing Cancer Immunotherapies Combining a cytotoxin and immune modulator gives potential to: • Act alone by
Slide 25: Novel Mechanism of Action Differentiates iADC from Other Immunotherapies
Novel Mechanism of Action Differentiates iADC from Other Immunotherapies Sutro iADCs bridge innate and adaptive immunity to provide broad Sutro STING / PD-1 / CAR-T protection in a single molecule ISAC Vaccine iADC TLR PDL-1 Cells Molecule Targeted and Chemo Mixed ADC Ab Biologic Biologic homogeneou
Slide 26: Boehringer Ingelheim BioXcellence Collaboration: First-in-class Cell-free Manufacturing at Commercial Scale
26 Boehringer Ingelheim BioXcellence Collaboration: Established First-in-class Cell-free Manufacturing Capabilities at Commercial Scale First-ever manufacturing of a cell-free ADC to large-scale GMP production, marking an industry milestone Proprietary Cell-free XpressCF® Platform Advantages: • Modu
Slide 27: Broad Pipeline Driven by Cell-free Technology
Broad Pipeline Driven by Cell-free Technology WORLDWIDE OR PHASE 3/ GEOGRAPHIC PROGRAM MODALITY/TARGET INDICATION DISCOVERY PRECLINICAL PHASE 1/1B PHASE 2 REGISTRATIONAL PARTNER SUTRO-LED PROGRAMS Ovarian Cancer Ovarian Cancer Luveltamab (bevacizumab combo) tazevibulin FRα Antibody-Drug Endometrial
Sutro Biopharma — 43rd Annual J.P. Morgan Healthcare Conference (January 2025) on 6ix